JP2023547523A5 - - Google Patents
Info
- Publication number
- JP2023547523A5 JP2023547523A5 JP2023526938A JP2023526938A JP2023547523A5 JP 2023547523 A5 JP2023547523 A5 JP 2023547523A5 JP 2023526938 A JP2023526938 A JP 2023526938A JP 2023526938 A JP2023526938 A JP 2023526938A JP 2023547523 A5 JP2023547523 A5 JP 2023547523A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- hcdr
- lcdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206567 | 2020-11-10 | ||
| EP20206567.8 | 2020-11-10 | ||
| EP21155823.4 | 2021-02-08 | ||
| EP21155823 | 2021-02-08 | ||
| EP21172623 | 2021-05-07 | ||
| EP21172623.7 | 2021-05-07 | ||
| EP21187472.2 | 2021-07-23 | ||
| EP21187472 | 2021-07-23 | ||
| PCT/EP2021/080888 WO2022101120A1 (en) | 2020-11-10 | 2021-11-08 | Prevention or mitigation of t-cell engaging agent-related adverse effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023547523A JP2023547523A (ja) | 2023-11-10 |
| JP2023547523A5 true JP2023547523A5 (https=) | 2024-11-14 |
Family
ID=78528969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526938A Pending JP2023547523A (ja) | 2020-11-10 | 2021-11-08 | Ｔ細胞係合剤関連の有害作用の防止又は軽減 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220168418A1 (https=) |
| EP (1) | EP4243856A1 (https=) |
| JP (1) | JP2023547523A (https=) |
| KR (1) | KR20230107235A (https=) |
| AU (1) | AU2021380807A1 (https=) |
| CA (1) | CA3196810A1 (https=) |
| IL (1) | IL302570A (https=) |
| MX (1) | MX2023005306A (https=) |
| TW (1) | TW202233231A (https=) |
| WO (1) | WO2022101120A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| LT2961771T (lt) | 2013-02-26 | 2020-03-10 | Roche Glycart Ag | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams |
| EP3177643B1 (en) | 2014-08-04 | 2019-05-08 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| EP3233918A1 (en) * | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| KR20230148844A (ko) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| WO2018220099A1 (en) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| SG11201900344YA (en) * | 2016-07-15 | 2019-02-27 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| WO2020169698A1 (en) * | 2019-02-21 | 2020-08-27 | F. Hoffmann-La Roche Ag | Sensitization of cancer cells to tnf by bet inhibition |
-
2021
- 2021-11-08 WO PCT/EP2021/080888 patent/WO2022101120A1/en not_active Ceased
- 2021-11-08 MX MX2023005306A patent/MX2023005306A/es unknown
- 2021-11-08 CA CA3196810A patent/CA3196810A1/en active Pending
- 2021-11-08 IL IL302570A patent/IL302570A/en unknown
- 2021-11-08 EP EP21802750.6A patent/EP4243856A1/en active Pending
- 2021-11-08 AU AU2021380807A patent/AU2021380807A1/en active Pending
- 2021-11-08 KR KR1020237015673A patent/KR20230107235A/ko active Pending
- 2021-11-08 JP JP2023526938A patent/JP2023547523A/ja active Pending
- 2021-11-09 TW TW110141678A patent/TW202233231A/zh unknown
- 2021-11-09 US US17/454,193 patent/US20220168418A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023547523A5 (https=) | ||
| KR101092132B1 (ko) | 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와 관련된 혈액학적 악성종양의 치료법 | |
| JP2024156736A5 (https=) | ||
| Remberger et al. | Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation | |
| JP2024514281A5 (https=) | ||
| JP2021509009A5 (https=) | ||
| JP2018512170A5 (https=) | ||
| CN103933573A (zh) | 用于治疗免疫病症的联合治疗 | |
| JP2023542212A5 (https=) | ||
| CN111683677A (zh) | 使用抗体-药物缀合物调节免疫应答 | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| Di Filippo | Anti‐IL‐2 receptor antibody vs. polyclonal anti‐lymphocyte antibody as induction therapy in pediatric transplantation | |
| KR20240046170A (ko) | B-세포 악성종양의 치료에 사용하기 위한 조성물 | |
| JP7492752B2 (ja) | 免疫療法のためのアジュバントとしてのグアナベンズ | |
| CN102245205A (zh) | 用于减少b-辅助性t细胞以治疗自身免疫疾病的方法 | |
| JP2023546657A5 (https=) | ||
| Schattner et al. | Natural killer cells—toward clinical application | |
| KR20230005142A (ko) | 인터루킨 억제제와 조합된 clever-1 억제제를 통한 질환의 치료 | |
| CN1527840A (zh) | Cd25结合分子在类固醇耐受型患者中的用途 | |
| WO2018085775A1 (en) | Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor | |
| RU2318537C2 (ru) | Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам | |
| Durlik | Treatment of antibody-mediated rejection in kidney transplantation | |
| WO2025021587A1 (en) | Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof | |
| CN121693348A (zh) | 肿瘤联合治疗及使用方法 | |
| HK1161088A (en) | Methods to reduce b-helper t cells to treat autoimmune diseases |